

Recombinant Cynomolgus Interleukin-17A/IL-17A (C-6His)

Catalog No. PKSQ050109

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	Interleukin-17A;IL-17;IL-17A;Cytotoxic T-Lymphocyte-Associated Antigen 8;CTLA-8;IL17A;CTLA8;IL17
Species	Cynomolgus macaques
Expression Host	HEK293 Cells
Sequence	Gly24-Ala155
Accession	G7P4U9
Calculated Molecular Weight	15.9 kDa
Observed molecular weight	15-25 kDa
Tag	C-His
Bioactivity	Immobilized Cynomolgus IL-17A-His (Cat#PKSQ050109) at 10 µg/ml (100 µl/well) can bind Anti-Human IL-17A mAb. The ED50 of Anti-Human IL-17A mAb is 128 ng/ml.


Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.



Immobilized Cynomolgus IL-17A-His (Cat#PKSQ050109) at 10 µg/ml (100 µl/well) can bind Anti-Human IL-17A mAb. The ED50 of Anti-Human IL-17A mAb is 128 ng/ml.

For Research Use Only

Background

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.